Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease.

The Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway constitute the fulcrum in many vital cellular processes, including cell growth, differentiation, proliferation, and regulatory immune functions. Various cytokines, growth factors, and protein tyrosine kinases communicate through the JAK/STAT pathway and regulate the transcription of numerous genes. In addition to their critical roles in a plethora of key cellular activities, the JAK/STAT signaling pathways also have been implicated in the pathogenesis of several diseases, including inflammatory bowel disease (IBD), especially since a JAK inhibitor recently has been shown to be effective in the treatment of ulcerative colitis. The aim of this review is to highlight the recent findings on the regulatory mechanism of JAK/STAT signaling pathways and to reveal the evolving comprehension of their interface which might be of interest for clinicians involved in IBD therapy. Further, it is described how these signaling pathways have been exploited for the development of promising novel JAK inhibitors with anti-inflammatory effects verified in clinical trials.

[1]  Riitta Lahesmaa,et al.  Genomic views of STAT function in CD4+ T helper cell differentiation , 2011, Nature Reviews Immunology.

[2]  Susan D. Spencer,et al.  The Orphan Receptor CRF2-4 Is an Essential Subunit of the Interleukin 10 Receptor , 1998, The Journal of experimental medicine.

[3]  J. Darnell,et al.  The JAK-STAT pathway at twenty. , 2012, Immunity.

[4]  Pavel Kovarik,et al.  Serine phosphorylation of STATs , 2000, Oncogene.

[5]  M. Altfeld,et al.  Increased proportion of CD16+ NK cells in the colonic lamina propria of inflammatory bowel disease patients, but not after azathioprine treatment , 2010, Alimentary pharmacology & therapeutics.

[6]  Thomas Korn,et al.  IL-17 and Th17 Cells. , 2009, Annual review of immunology.

[7]  M. Neurath,et al.  Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. , 1996, Journal of immunology.

[8]  S. Landas,et al.  Immune markers and differential signaling networks in ulcerative colitis and Crohn's disease , 2012, Inflammatory bowel diseases.

[9]  D. Aaronson,et al.  A Road Map for Those Who Don't Know JAK-STAT , 2002, Science.

[10]  R. Morita,et al.  Low dose CP-690,550 (tofacitinib), a pan-JAK inhibitor, accelerates the onset of experimental autoimmune encephalomyelitis by potentiating Th17 differentiation. , 2012, Biochemical and biophysical research communications.

[11]  Kathryn Roeder,et al.  Genome-wide association identifies multiple ulcerative colitis susceptibility loci , 2010, Nature Genetics.

[12]  A. Rudensky,et al.  Regulatory T cells: mechanisms of differentiation and function. , 2012, Annual review of immunology.

[13]  D. Levy,et al.  Targeted Disruption of the Mouse Stat1 Gene Results in Compromised Innate Immunity to Viral Disease , 1996, Cell.

[14]  E. Chi,et al.  Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. , 2008, Immunity.

[15]  R. Xavier,et al.  Genetics and pathogenesis of inflammatory bowel disease , 2011, Nature.

[16]  Tamas Koncz,et al.  Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial , 2013, The Lancet.

[17]  W. Strober,et al.  Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. , 2011, Gastroenterology.

[18]  B. Gao,et al.  STAT proteins - key regulators of anti-viral responses, inflammation, and tumorigenesis in the liver. , 2012, Journal of hepatology.

[19]  B. Becher,et al.  RORgamma-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F. , 2009, Gastroenterology.

[20]  T. Okanoue,et al.  Involvement of IL-17A in the pathogenesis of DSS-induced colitis in mice. , 2008, Biochemical and biophysical research communications.

[21]  Ozge Canli,et al.  gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. , 2009, Cancer cell.

[22]  Michael P. Brown,et al.  Stat5a and Stat5b Proteins Have Essential and Nonessential, or Redundant, Roles in Cytokine Responses , 1998, Cell.

[23]  Jianfei Yang,et al.  Interleukin 10 suppresses Th17 cytokines secreted by macrophages and T cells , 2008, European journal of immunology.

[24]  David Díaz-Jiménez,et al.  Characterization of the novel ST2/IL‐33 system in patients with inflammatory bowel disease , 2010, Inflammatory bowel diseases.

[25]  Clara Abraham,et al.  Interactions between the host innate immune system and microbes in inflammatory bowel disease. , 2011, Gastroenterology.

[26]  W. Tremaine,et al.  American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. , 2006, Gastroenterology.

[27]  J. Marto,et al.  Regulation of Jak2 Function by Phosphorylation of Tyr317 and Tyr637 during Cytokine Signaling , 2009, Molecular and Cellular Biology.

[28]  Qiang Xu,et al.  Inhibition of Th1/Th17 responses via suppression of STAT1 and STAT3 activation contributes to the amelioration of murine experimental colitis by a natural flavonoid glucoside icariin. , 2013, Biochemical pharmacology.

[29]  N. Sato,et al.  JAK2 associates with the beta c chain of the receptor for granulocyte-macrophage colony-stimulating factor, and its activation requires the membrane-proximal region , 1994, Molecular and cellular biology.

[30]  T. Nomura,et al.  Control of Regulatory T Cell Development by the Transcription Factor Foxp3 , 2002 .

[31]  P. Doherty,et al.  Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells , 1996, Nature.

[32]  B. Müller-Myhsok,et al.  Role of the novel Th17 cytokine IL‐17F in inflammatory bowel disease (IBD): Upregulated colonic IL‐17F expression in active Crohn's disease and analysis of the IL17F p.His161Arg polymorphism in IBD , 2008, Inflammatory bowel diseases.

[33]  J. O’Shea,et al.  Janus kinases in immune cell signaling , 2009, Immunological reviews.

[34]  O. Nielsen,et al.  MAP kinases in inflammatory bowel disease. , 2011, Clinica chimica acta; international journal of clinical chemistry.

[35]  Richard A Flavell,et al.  The Transcription Factor GATA-3 Is Necessary and Sufficient for Th2 Cytokine Gene Expression in CD4 T Cells , 1997, Cell.

[36]  T. Boggon,et al.  JAK3: a two-faced player in hematological disorders. , 2009, The international journal of biochemistry & cell biology.

[37]  M. Peppelenbosch,et al.  New insights into the role of STAT3 in IBD , 2012, Inflammatory bowel diseases.

[38]  S. Brand.  Crohn’s disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn’s disease , 2009, Gut.

[39]  Y. Yang,et al.  JAK1 kinase forms complexes with interleukin-4 receptor and 4PS/insulin receptor substrate-1-like protein and is activated by interleukin-4 and interleukin-9 in T lymphocytes. , 1994, The Journal of biological chemistry.

[40]  E. Lee,et al.  Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. , 2012, The New England journal of medicine.

[41]  P. Dobrzanski,et al.  The many faces of Janus kinase. , 2012, Biochemical pharmacology.

[42]  A. Andoh,et al.  Increased expression of interleukin 17 in inflammatory bowel disease , 2003, Gut.

[43]  A. Cumano,et al.  Jak2 Deficiency Defines an EssentialDevelopmental Checkpoint in DefinitiveHematopoiesis , 1998, Cell.

[44]  E. Liu,et al.  Involvement of the Jak-3 Janus kinase in signalling by interleukins 2 and 4 in lymphoid and myeloid cells , 1994, Nature.

[45]  L. Denson,et al.  Deletion of Intestinal Epithelial Cell STAT3 Promotes T-Lymphocyte STAT3 Activation and Chronic Colitis Following Acute Dextran Sodium Sulfate Injury in Mice , 2013, Inflammatory bowel diseases.

[46]  W. Leonard,et al.  Mutation of Jak3 in a Patient with SCID: Essential Role of Jak3 in Lymphoid Development , 1995, Science.

[47]  V. Kuchroo,et al.  Induction and effector functions of TH17 cells , 2008, Nature.

[48]  J. Kremer,et al.  Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. , 2012, The New England journal of medicine.

[49]  J. Johnston,et al.  Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID) , 1995, Nature.

[50]  N. K. Williams,et al.  Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains. , 2009, Journal of molecular biology.

[51]  Nonredundant roles for Stat5a/b in directly regulating Foxp3. , 2007, Blood.

[52]  P. Heinrich,et al.  Structural requirements of the interleukin-6 signal transducer gp130 for its interaction with Janus kinase 1: the receptor is crucial for kinase activation. , 2002, The Biochemical journal.

[53]  A. Miyajima,et al.  Interleukin‐3, granulocyte‐macrophage colony stimulating factor and interleukin‐5 transduce signals through two STAT5 homologs. , 1995, The EMBO journal.

[54]  R. Plenge,et al.  JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. , 2012, Immunity.

[55]  P. Igaz,et al.  Biological and clinical significance of the JAK-STAT pathway; lessons from knockout mice , 2001, Inflammation Research.

[56]  O. Silvennoinen,et al.  The Janus kinases (Jaks) , 2004, Genome Biology.

[57]  Rudi Beyaert,et al.  Enterocyte death and intestinal barrier maintenance in homeostasis and disease. , 2011, Trends in molecular medicine.

[58]  S. Akira,et al.  Correction: Stat3 Activation Is Responsible for IL-6–Dependent T Cell Proliferation through Preventing Apoptosis: Generation and Characterization of T Cell–Specific Stat3-Deficient Mice , 2015, The Journal of Immunology.

[59]  H. Pircher,et al.  Partial impairment of cytokine responses in Tyk2-deficient mice. , 2000, Immunity.

[60]  J. Arthur,et al.  Inhibition of JAKs in Macrophages Increases Lipopolysaccharide-Induced Cytokine Production by Blocking IL-10–Mediated Feedback , 2012, The Journal of Immunology.

[61]  S. Akira,et al.  Impaired IL-13-mediated functions of macrophages in STAT6-deficient mice. , 1996, Journal of immunology.

[62]  Tariq Ahmad,et al.  Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47 , 2011, Nature Genetics.

[63]  David E Levy,et al.  The transcription factor STAT3 is required for T helper 2 cell development. , 2011, Immunity.

[64]  Laurie H Glimcher,et al.  A Novel Transcription Factor, T-bet, Directs Th1 Lineage Commitment , 2000, Cell.

[65]  Dustin E. Schones,et al.  Priming for T helper type 2 differentiation by interleukin 2-mediated induction of IL-4 receptor α chain expression , 2008, Nature Immunology.

[66]  D. Pardoll,et al.  Metabolic control of the Treg/Th17 axis , 2013, Immunological reviews.

[67]  J. O’Shea,et al.  Janus kinase inhibitors in autoimmune diseases , 2013, Annals of the rheumatic diseases.

[68]  S. Lynch,et al.  Role of the microbiota in inflammatory bowel diseases. , 2012, Inflammatory bowel diseases.

[69]  M. Kamm,et al.  Characteristics of intestinal dendritic cells in inflammatory bowel diseases. , 2005, Gastroenterology.

[70]  S. Yamasaki,et al.  Inhibitory effects of the JAK inhibitor CP690,550 on human CD4+ T lymphocyte cytokine production , 2011, BMC Immunology.

[71]  R. Sartor.  Mechanisms of Disease: pathogenesis of Crohn's disease and ulcerative colitis , 2006, Nature Clinical Practice Gastroenterology &Hepatology.

[72]  W. Sandborn,et al.  Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. , 2012, The New England journal of medicine.

[73]  G. Stark,et al.  Complementation by the protein tyrosine kinase JAK2 of a mutant cell line defective in the interferon-& gamma; signal transduction pathway , 1993, Nature.

[74]  W. Sandborn,et al.  Phase 2 Randomized Study of CP-690,550, an Oral Janus Kinase Inhibitor, in Active Crohn's Disease , 2011 .

[75]  J. Darnell,et al.  Signalling: STATs: transcriptional control and biological impact , 2002, Nature Reviews Molecular Cell Biology.

[76]  S. Akira,et al.  Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[77]  C. Mueller,et al.  Intestinal macrophages: differentiation and involvement in intestinal immunopathologies , 2009, Seminars in Immunopathology.

[78]  J. Hampe,et al.  Activation of signal transducer and activator of transcription (STAT) 1 in human chronic inflammatory bowel disease , 2002, Gut.

[79]  W. Sandborn,et al.  Crohn's disease , 2012, The Lancet.

[80]  A. Rudensky,et al.  CD4+ Regulatory T Cells Control TH17 Responses in a Stat3-Dependent Manner , 2009, Science.

[81]  J. Casanova,et al.  Inborn errors of human JAKs and STATs. , 2012, Immunity.

[82]  E. Fikrig,et al.  STAT3 deletion during hematopoiesis causes Crohn's disease-like pathogenesis and lethality: A critical role of STAT3 in innate immunity , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[83]  D. Littman,et al.  Plasticity of CD4+ T cell lineage differentiation. , 2009, Immunity.

[84]  Francisco Guarner,et al.  The gut microbiota in IBD , 2012, Nature Reviews Gastroenterology &Hepatology.

[85]  M. Neurath,et al.  Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn disease and experimental colitis in vivo , 2000, Nature Medicine.

[86]  K. Shuai,et al.  Regulation of JAK–STAT signalling in the immune system , 2003, Nature Reviews Immunology.

[87]  C. Deng,et al.  Inactivation of Stat5 in Mouse Mammary Epithelium during Pregnancy Reveals Distinct Functions in Cell Proliferation, Survival, and Differentiation , 2004, Molecular and Cellular Biology.

[88]  W. Paul,et al.  Stat6 Is Necessary and Sufficient for IL-4’s Role in Th2 Differentiation and Cell Expansion , 2001, The Journal of Immunology.

[89]  J. Kolls,et al.  Targeting IL-17 and TH17 cells in chronic inflammation , 2012, Nature Reviews Drug Discovery.

[90]  P. Dentelli,et al.  Signal Transducers and Activators of Transcription 3 Signaling Pathway: An Essential Mediator of Inflammatory Bowel Disease and Other Forms of Intestinal Inflammation , 2005, Inflammatory bowel diseases.

[91]  Tariq Ahmad,et al.  Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci , 2010, Nature Genetics.

[92]  Steven M Holland,et al.  JAKs and STATs in immunity, immunodeficiency, and cancer. , 2013, The New England journal of medicine.

[93]  J. Yamamoto-Furusho,et al.  Role of cytokines in inflammatory bowel disease. , 2008, World journal of gastroenterology.

[94]  N. Pace,et al.  Disease phenotype and genotype are associated with shifts in intestinal‐associated microbiota in inflammatory bowel diseases , 2011, Inflammatory bowel diseases.

[95]  P. Musiani,et al.  Induced somatic inactivation of STAT3 in mice triggers the development of a fulminant form of enterocolitis. , 2004, Cytokine.

[96]  Wei Wu,et al.  Janus kinase 3: the controller and the controlled. , 2012, Acta biochimica et biophysica Sinica.

[97]  G. Stark,et al.  The protein tyrosine kinase JAK1 complements defects in interferon-α/β and -γ signal transduction , 1993, Nature.

[98]  P. Gregersen,et al.  Structural biology of shared cytokine receptors. , 2009, Annual review of immunology.

[99]  A. Rudensky,et al.  Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation. , 2011, Immunity.

[100]  A. Andoh,et al.  Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice. , 2004, Clinical immunology.

[101]  Courtney R. Plumlee,et al.  Inteferons pen the JAK-STAT pathway. , 2008, Seminars in cell & developmental biology.

[102]  R. Schreiber,et al.  Disruption of the Jak1 Gene Demonstrates Obligatory and Nonredundant Roles of the Jaks in Cytokine-Induced Biologic Responses , 1998, Cell.

[103]  A. Svejgaard,et al.  Constitutive STAT3 Activation in Intestinal T Cells from Patients with Crohn's Disease* , 2003, The Journal of Biological Chemistry.

[104]  W. Paul,et al.  Stat5 activation plays a critical role in Th2 differentiation. , 2003, Immunity.

[105]  F. Powrie,et al.  CD4+ T-cell subsets in intestinal inflammation , 2013, Immunological reviews.

[106]  S. Akira,et al.  Cis3/Socs3/Ssi3 Plays a Negative Regulatory Role in Stat3 Activation and Intestinal Inflammation , 2001, The Journal of experimental medicine.

[107]  Jianfei Yang,et al.  T-bet is a STAT1-induced regulator of IL-12R expression in naïve CD4+ T cells , 2002, Nature Immunology.

[108]  John J. O’Shea,et al.  Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550) , 2011, The Journal of Immunology.

[109]  R. Kiesslich,et al.  Activation Pattern of Signal Transducers and Activators of Transcription (STAT) Factors in Inflammatory Bowel Diseases , 2005, The American Journal of Gastroenterology.

[110]  Richard A Flavell,et al.  A protective function for interleukin 17A in T cell–mediated intestinal inflammation , 2009, Nature Immunology.

[111]  Judy H. Cho,et al.  Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease , 2008, Nature Genetics.

[112]  Hiu Kiu,et al.  Biology and significance of the JAK/STAT signalling pathways , 2012, Growth factors.

[113]  C. Jobin,et al.  Mu opioid signaling protects against acute murine intestinal injury in a manner involving Stat3 signaling. , 2011, The American journal of pathology.

[114]  P. Mannon,et al.  Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. , 2004, The Journal of clinical investigation.

[115]  K. Rajewsky,et al.  Interleukin-10-deficient mice develop chronic enterocolitis , 1993, Cell.

[116]  S. Danese.  New therapies for inflammatory bowel disease: from the bench to the bedside , 2011, Gut.

[117]  S. Brand,et al.  The role of the novel Th17 cytokine IL-26 in intestinal inflammation , 2008, Gut.

[118]  Gisen Kim,et al.  Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis , 2009, Nature Immunology.

[119]  J. O’Shea,et al.  Diverse targets of the transcription factor STAT3 contribute to T cell pathogenicity and homeostasis. , 2010, Immunity.

[120]  L. Cosmi,et al.  Phenotypic and functional features of human Th17 cells , 2007, The Journal of experimental medicine.

[121]  D. Littman,et al.  The Orphan Nuclear Receptor RORγt Directs the Differentiation Program of Proinflammatory IL-17+ T Helper Cells , 2006, Cell.

[122]  J. Gordon,et al.  Homeostasis and Inflammation in the Intestine , 2010, Cell.

[123]  T. Karlsen,et al.  Replication of signals from recent studies of Crohn's disease identifies previously unknown disease loci for ulcerative colitis , 2008, Nature Genetics.

[124]  Chen Dong,et al.  STAT3 Regulates Cytokine-mediated Generation of Inflammatory Helper T Cells* , 2007, Journal of Biological Chemistry.

[125]  C. Schindler,et al.  Immune response in Stat2 knockout mice. , 2000, Immunity.

[126]  S. Akira,et al.  Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. , 1999, Immunity.

[127]  Min Zhuo,et al.  The JAK/STAT Pathway Is Involved in Synaptic Plasticity , 2012, Neuron.

[128]  K. Sugimoto.  Role of STAT3 in inflammatory bowel disease. , 2008, World Journal of Gastroenterology.

[129]  Kenneth M. Murphy,et al.  Decision making in the immune system: The lineage decisions of helper T cells , 2002, Nature Reviews Immunology.

[130]  R. Broaddus,et al.  Regulation of inflammatory responses by IL-17F , 2008, The Journal of experimental medicine.

[131]  W. Leonard,et al.  New insights into the regulation of T cells by γc family cytokines , 2009, Nature Reviews Immunology.

[132]  L. Ivashkiv,et al.  Signaling by STATs , 2004, Arthritis research & therapy.

[133]  K. Herrmann,et al.  IL-22 is increased in active Crohn's disease and promotes proinflammatory gene expression and intestinal epithelial cell migration. , 2006, American journal of physiology. Gastrointestinal and liver physiology.

[134]  Fiona Powrie,et al.  Intestinal homeostasis and its breakdown in inflammatory bowel disease , 2011, Nature.

[135]  Toshio Hirano,et al.  IL-6-gp130-STAT3 in T cells directs the development of IL-17+ Th with a minimum effect on that of Treg in the steady state. , 2007, International immunology.

[136]  Hiroshi Nakajima,et al.  Janus kinase 3 (Jak3) is essential for common cytokine receptor γ chain (γc)-dependent signaling: comparative analysis of γc, Jak3, and γc and Jak3 double-deficient mice , 2000 .

[137]  S. Bhattacharya,et al.  Signaling through the JAK/STAT pathway, recent advances and future challenges. , 2002, Gene.

[138]  David C. Wilson,et al.  Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease , 2012, Nature.